Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model

D M Barratt; K Van Meter; P Asmar; T Nolan; C Trahan; L Garcia-Covarrubias; S E Metzinger

doi:10.1128/AAC.45.12.3601-3602.2001

Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model

Antimicrob Agents Chemother. 2001 Dec;45(12):3601-2. doi: 10.1128/AAC.45.12.3601-3602.2001.

Authors

D M Barratt¹, K Van Meter, P Asmar, T Nolan, C Trahan, L Garcia-Covarrubias, S E Metzinger

Affiliation

¹ Section of Emergency Medicine and Hyperbaric Medicine, Department of Medicine, Louisiana State University, New Orleans, Louisiana 70112, USA. dbarratt@bellsouth.net

Abstract

Zygomycosis was induced by injecting CD-1 mice with 5 mg of intraperitoneal deferoxamine and then 10(6) CFU of intravenous and intrasinus Rhizopus arrhizus. The addition of hyperbaric oxygen (2.0 atm absolute twice daily) to amphotericin B did not improve survival over that achieved with amphotericin B and placebo air treatments.

MeSH terms

Amphotericin B / therapeutic use
Animals
Antifungal Agents / therapeutic use
Combined Modality Therapy
Deferoxamine / pharmacology
Female
Hyperbaric Oxygenation*
Mice
Mucormycosis / drug therapy
Mucormycosis / therapy*
Rhizopus*
Survival Analysis

Substances

Antifungal Agents
Amphotericin B
Deferoxamine